Awaiting development: Guidance and quality standards

Showing 151 to 160 of 335

Guidance and quality standards awaiting development
Title	Type
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]	Technology appraisal guidance
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer	Interventional procedures guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance
LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance
LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]	Technology appraisal guidance